HPS Pharmacies wish to give notice that Pfizer Australia is experiencing a supply interruption for Nitrostat® tablets as follows:
Glyceryl Trinitrate 300mcg
Normal supplies of Nitrostat® 300mcg sublingual tablets are expected to resume by the 14th February 2020. Nitrostat® 600mcg sublingual tablets are currently available.
Nitrostat® is an internationally registered brand of glyceryl trinitrate tablets. It has been approved for supply under Section 19A of the Therapeutic Goods Act 1989 while the Australian registered brands, Lycinate® and Anginine®, experience a long-term supply interruption. Normal supplies of Lycinate® and Anginine® 600mcg tablets are expected to resume by the end of December 2020.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, or Pfizer Australia on 1800 629 921.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates